ProteinQure is building the world’s leading AI platform for peptide drug design, focused on extracellular targets. Our lead program, PQ203 for TOP1-resistant triple-negative breast cancer—a disease with no approved treatment options—has just entered Phase I trials in the US and Canada.
Our platform has been validated in collaborations with four of the top 25 pharmaceutical companies and leverages proprietary physics-based methods to explore the largest accessible chemical space, spanning full scaffold diversity and more than 3,500 non-canonical building blocks.
Beyond partnerships, we are advancing internal programs that use novel peptides to enable tissue-specific payload delivery, including next-generation approaches for siRNA delivery to the CNS.
Rating Reviews
Rating is calculated based on
1
review and is evolving.
Pros: I really appreciate the scientific focus here. It's exciting to work on novel protein therapeutics and contribute to potentially life-changing treatments. The R&D team is sharp, and there's a genuine sense of shared purpose. The location in Toronto is also a major plus for networking and access to talent in the Canadian biotech hub.
Cons: As a growing company, there are sometimes bottlenecks in internal processes and procurement, which can slow down research. Communication between departments could also be more streamlined. While job security is decent for now, it feels tied to funding rounds, as is common in early-stage biopharma.
Advice to Management: Continue to invest in R&D and foster cross-departmental collaboration. Clearer communication on long-term strategy and funding will help build confidence and align efforts.
Show more
Does ProteinQure offer good sick leave benefits for its employees in the biotech industry?
Yes, ProteinQure provides comprehensive sick leave, which I've found to be supportive during personal health needs, reflecting their commitment to employee well-being in the competitive San Francisco biotech scene.
CA
